MoneyWorks4Me

Themis Medicare informs about press release

17 Feb 2023 Evaluate
In terms of Regulation 30 of the SEBI (LODR) Regulations, 2015, Themis Medicare has informed that it enclosed a copy of the press release titled - Themis Medicare announces DCGI approval of Remifentanil Hydrochloride 1mg/2mg for injection for import and marketing. 

The above information is a part of company’s filings submitted to BSE.
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..